Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Meng Chai(Capital Medical University), Ping Qiao, Guoyan Zhao(Washington University in St. Louis), Lei Qian, Dongmei Shi(Weifang University), Haoyu Li(Central South University), Yuyang Liu(Capital Medical University), Pei An(Peking University), Yujie Zhou(Wuhan University), Yong‐Ming He(Soochow University), Xuebin Han(Shanxi Cardiovascular Hospital), Zhao Wang(Hainan University), Wei Han, Huan Deng(Nanchang University), Shuling Yan, Qingyang Ma, Xueping Ma(Nanjing General Hospital of Nanjing Military Command)
BMC Medicine
February 28, 2023
Cited by 50


Related Papers